BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Piqué JM, Panés J. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96. [PMID: 10861269 DOI: 10.1136/gut.47.1.88] [Cited by in Crossref: 98] [Cited by in F6Publishing: 102] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Hey-hadavi J, Velisetty P, Mhatre S. Trends and recent developments in pharmacotherapy of acute pancreatitis. Postgraduate Medicine 2022. [DOI: 10.1080/00325481.2022.2136390] [Reference Citation Analysis]
2 Hong L, Chen G, Cai Z, Liu H, Zhang C, Wang F, Xiao Z, Zhong J, Wang L, Wang Z, Cui W. Balancing Microthrombosis and Inflammation via Injectable Protein Hydrogel for Inflammatory Bowel Disease. Adv Sci (Weinh) 2022;:e2200281. [PMID: 35524641 DOI: 10.1002/advs.202200281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Hofbauer TM, Ondracek AS, Lang IM. Neutrophil Extracellular Traps in Atherosclerosis and Thrombosis. Handb Exp Pharmacol 2022;270:405-25. [PMID: 33459876 DOI: 10.1007/164_2020_409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cenko E, Badimon L, Bugiardini R, Claeys MJ, De Luca G, de Wit C, Derumeaux G, Dorobantu M, Duncker DJ, Eringa EC, Gorog DA, Hassager C, Heinzel FR, Huber K, Manfrini O, Milicic D, Oikonomou E, Padro T, Trifunovic-Zamaklar D, Vasiljevic-Pokrajcic Z, Vavlukis M, Vilahur G, Tousoulis D. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovasc Res 2021:cvab298. [PMID: 34528075 DOI: 10.1093/cvr/cvab298] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 24.0] [Reference Citation Analysis]
5 Sleutjes JAM, van Lennep JER, van der Woude CJ, de Vries AC. Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therap Adv Gastroenterol 2021;14:17562848211032126. [PMID: 34377149 DOI: 10.1177/17562848211032126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 Braz-de-Melo HA, Faria SS, Pasquarelli-do-Nascimento G, Santos IO, Kobinger GP, Magalhães KG. The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19. Front Med (Lausanne) 2021;8:615333. [PMID: 33968948 DOI: 10.3389/fmed.2021.615333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
7 Wang D, Lin Q, Du M, Zheng G, Xu W, Zhang H, Liu K. Protective effect of dexmedetomidine on perioperative myocardial injury in patients with Stanford type-A aortic dissection. Rev Assoc Med Bras (1992) 2020;66:1638-44. [PMID: 33331570 DOI: 10.1590/1806-9282.66.12.1638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine 2020;59:102969. [PMID: 32853989 DOI: 10.1016/j.ebiom.2020.102969] [Cited by in Crossref: 82] [Cited by in F6Publishing: 88] [Article Influence: 41.0] [Reference Citation Analysis]
9 Chaugule S, Kashipathi Sureshbabu S, Dakave S, Krishna CM, Chaudhari P, Indap M, Chiplunkar S. Hexane Fraction of Turbo brunneus Inhibits Intermediates of RANK-RANKL Signaling Pathway and Prevent Ovariectomy Induced Bone Loss. Front Endocrinol (Lausanne) 2019;10:608. [PMID: 31555218 DOI: 10.3389/fendo.2019.00608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hu H, Xu Y, Deng X, Luo Z, Zhou L, Shen M. Heparin-grafted PVA hydrogels: a material for the optical part of artificial cornea. Bioinspired, Biomimetic and Nanobiomaterials 2019;8:171-180. [DOI: 10.1680/jbibn.18.00013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Kim J, Jeong J, Ha R, Sunwoo W. Heparin therapy as adjuvant treatment for profound idiopathic sudden sensorineural hearing loss. Laryngoscope 2020;130:1310-5. [PMID: 31397902 DOI: 10.1002/lary.28231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Frossi B, De Carli M, Calabrò A. Coeliac Disease and Mast Cells. Int J Mol Sci 2019;20:E3400. [PMID: 31373285 DOI: 10.3390/ijms20143400] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
13 Tozlu M, Kayar Y, İnce AT, Baysal B, Şentürk H. Low molecular weight heparin treatment of acute moderate and severe pancreatitis: A randomized, controlled,open-label study. Turk J Gastroenterol 2019;30:81-7. [PMID: 30289392 DOI: 10.5152/tjg.2018.18583] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
14 Gao H, Lin Y, He J, Zhou S, Liang M, Huang C, Li X, Liu C, Zhang P. Role of heparan sulfate in the Zika virus entry, replication, and cell death. Virology 2019;529:91-100. [PMID: 30684694 DOI: 10.1016/j.virol.2019.01.019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
15 Lê BV, Jandrot-Perrus M, Couture C, Checkmahomed L, Venable MC, Hamelin MÈ, Boivin G. Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice. J Gen Virol 2018;99:1367-80. [PMID: 30102144 DOI: 10.1099/jgv.0.001135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Wat JM, Audette MC, Kingdom JC. Molecular actions of heparin and their implications in preventing pre-eclampsia. J Thromb Haemost 2018. [PMID: 29877031 DOI: 10.1111/jth.14191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
17 Zhang K, Liu Y, Zhao X, Tang Q, Dernedde J, Zhang J, Fan H. Anti-inflammatory properties of GLPss58, a sulfated polysaccharide from Ganoderma lucidum. International Journal of Biological Macromolecules 2018;107:486-93. [DOI: 10.1016/j.ijbiomac.2017.09.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
18 Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost 2017;117:437-44. [DOI: 10.1160/th16-08-0620] [Cited by in Crossref: 123] [Cited by in F6Publishing: 178] [Article Influence: 24.6] [Reference Citation Analysis]
19 Machfoed MH, Kurniawan M, Usman FS. Review article: DOES INTRA-ARTERIAL HEPARIN FLUSHING (IAHF) CAN ACTUALLY INCREASE MANUAL MUSCLE TEST (MMT) SCORE IN CHRONIC ISCHEMIC STROKE PATIENTS? FMI 2017;52:148. [DOI: 10.20473/fmi.v52i2.5232] [Reference Citation Analysis]
20 Yang G, Chen X, Yan Z, Zhu Q, Yang C. CD11b promotes the differentiation of osteoclasts induced by RANKL through the spleen tyrosine kinase signalling pathway. J Cell Mol Med 2017;21:3445-52. [PMID: 28661042 DOI: 10.1111/jcmm.13254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
21 Lipowsky HH, Lescanic A. Inhibition of inflammation induced shedding of the endothelial glycocalyx with low molecular weight heparin. Microvasc Res 2017;112:72-8. [PMID: 28347755 DOI: 10.1016/j.mvr.2017.03.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
22 Ghezzi S, Cooper L, Rubio A, Pagani I, Capobianchi MR, Ippolito G, Pelletier J, Meneghetti MCZ, Lima MA, Skidmore MA, Broccoli V, Yates EA, Vicenzi E. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res 2017;140:13-7. [PMID: 28063994 DOI: 10.1016/j.antiviral.2016.12.023] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 13.6] [Reference Citation Analysis]
23 Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of Heparin and Related Drugs. Pharmacol Rev 2016;68:76-141. [PMID: 26672027 DOI: 10.1124/pr.115.011247] [Cited by in Crossref: 196] [Cited by in F6Publishing: 203] [Article Influence: 32.7] [Reference Citation Analysis]
24 Shastri MD, Stewart N, Horne J, Zaidi ST, Sohal SS, Peterson GM, Korner H, Gueven N, Patel RP. Non-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic Individuals. PLoS One 2015;10:e0128803. [PMID: 26046354 DOI: 10.1371/journal.pone.0128803] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
25 Mathieu C, Dhondt KP, Châlons M, Mély S, Raoul H, Negre D, Cosset FL, Gerlier D, Vivès RR, Horvat B. Heparan sulfate-dependent enhancement of henipavirus infection. mBio 2015;6:e02427. [PMID: 25759505 DOI: 10.1128/mBio.02427-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
26 Leal RF, Planell N, Kajekar R, Lozano JJ, Ordás I, Dotti I, Esteller M, Masamunt MC, Parmar H, Ricart E, Panés J, Salas A. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy. Gut 2015;64:233-42. [PMID: 24700437 DOI: 10.1136/gutjnl-2013-306518] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 13.4] [Reference Citation Analysis]
27 Saurim R, Koike MK, Bonservizi WG, Felix GA, Silva SM, Taha MO, Montero EF. Cardiac effect of ischemic preconditioning and heparin following intestinal ischemia and reperfusion in rats. Transplant Proc 2014;46:1852-6. [PMID: 25131053 DOI: 10.1016/j.transproceed.2014.05.055] [Reference Citation Analysis]
28 Raftery MJ, Lalwani P, Krautkrӓmer E, Peters T, Scharffetter-Kochanek K, Krüger R, Hofmann J, Seeger K, Krüger DH, Schönrich G. β2 integrin mediates hantavirus-induced release of neutrophil extracellular traps. J Exp Med 2014;211:1485-97. [PMID: 24889201 DOI: 10.1084/jem.20131092] [Cited by in Crossref: 126] [Cited by in F6Publishing: 128] [Article Influence: 15.8] [Reference Citation Analysis]
29 Kang JH, Hwang SR, Sung S, Jang JA, Alam MM, Sa KH, Kim S, Kim IS, Byun YR, Kang YM. Intracellular delivery of desulfated heparin with bile acid conjugation alleviates T cell-mediated inflammatory arthritis via inhibition of RhoA-dependent transcellular diapedesis. Journal of Controlled Release 2014;183:9-17. [DOI: 10.1016/j.jconrel.2014.03.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
30 Sudha T, Yalcin M, Lin HY, Elmetwally AM, Nazeer T, Arumugam T, Phillips P, Mousa SA. Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett 2014;350:25-33. [PMID: 24769074 DOI: 10.1016/j.canlet.2014.04.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
31 Shastri MD, Peterson GM, Stewart N, Sohal SS, Patel RP. Non-anticoagulant derivatives of heparin for the management of asthma: distant dream or close reality? Expert Opin Investig Drugs 2014;23:357-73. [PMID: 24387080 DOI: 10.1517/13543784.2014.866092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
32 Patel B, Gupta N, Ahsan F. Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma. J Aerosol Med Pulm Drug Deliv 2014;27:12-20. [PMID: 24286441 DOI: 10.1089/jamp.2013.1073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
33 Page C. Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol 2013;2013:910743. [PMID: 23984092 DOI: 10.1155/2013/910743] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
34 Xie-Zukauskas H, Das J, Short BL, Gutkind JS, Ray PE. Heparin inhibits angiotensin II-induced vasoconstriction on isolated mouse mesenteric resistance arteries through Rho-A- and PKA-dependent pathways. Vascul Pharmacol 2013;58:313-8. [PMID: 23268358 DOI: 10.1016/j.vph.2012.12.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
35 Lever R, Page CP. Non-anticoagulant effects of heparin: an overview. Handb Exp Pharmacol 2012;:281-305. [PMID: 22566229 DOI: 10.1007/978-3-642-23056-1_12] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
36 Li S, Cao G, Chen X, Wu T. Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2012;24:477-481. [PMID: 22293331 DOI: 10.1097/meg.0b013e328351097f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
37 Li S, Chen X, Wu T, Zhang M, Zhang X, Ji Z. Role of heparin on serum VEGF levels and local VEGF contents in reducing the severity of experimental severe acute pancreatitis in rats. Scandinavian Journal of Gastroenterology 2012;47:237-44. [DOI: 10.3109/00365521.2011.647063] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
38 Di Simone N, Di Nicuolo F, Castellani R, Veglia M, Tersigni C, Silano M, Tritarelli A, Scambia G, Marana R. Low-molecular-weight heparins induce decidual heparin-binding epidermal growth factor–like growth factor expression and promote survival of decidual cells undergoing apoptosis. Fertility and Sterility 2012;97:169-177.e1. [DOI: 10.1016/j.fertnstert.2011.10.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
39 D'ippolito S, Ortiz AS, Veglia M, Tersigni C, Di Simone N. Low Molecular Weight Heparin in Obstetric Care: A Review of the Literature. Reprod Sci 2011;18:602-13. [DOI: 10.1177/1933719111404612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
40 Mommsen P, Barkhausen T, Hildebrand F, Zeckey C, Krettek C, van Griensven M. Regulation of L-selectin expression by trauma-relevant cytokines. Pathol Res Pract 2011;207:142-7. [PMID: 21237580 DOI: 10.1016/j.prp.2010.12.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
41 Ferreira Chacon JM, Mello de Andrea ML, Blanes L, Ferreira LM. Effects of topical application of 10,000 IU heparin on patients with perineal dermatitis and second-degree burns treated in a public pediatric hospital. Journal of Tissue Viability 2010;19:150-8. [DOI: 10.1016/j.jtv.2010.03.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
42 Wang X, Chen Y, Song Y, Zhang S, Xie X, Wang X. Activated Syndecan-1 Shedding Contributes to Mice Colitis Induced by Dextran Sulfate Sodium. Dig Dis Sci 2011;56:1047-56. [DOI: 10.1007/s10620-010-1398-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
43 Murkin JM. Panvascular inflammation and mechanisms of injury in perioperative CNS outcomes. Semin Cardiothorac Vasc Anesth 2010;14:190-5. [PMID: 20656746 DOI: 10.1177/1089253210378177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
44 Mousa SA. Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond. In: Mousa SA, editor. Anticoagulants, Antiplatelets, and Thrombolytics. Totowa: Humana Press; 2010. pp. 109-32. [DOI: 10.1007/978-1-60761-803-4_3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
45 Lever R, Smailbegovic A, Page CP. Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity. European Journal of Pharmacology 2010;630:137-44. [DOI: 10.1016/j.ejphar.2009.12.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
46 Celasco G, Papa A, Jones R, Moro L, Bozzella R, Surace MM, Naccari GC, Gasbarrini G. Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX ® ) for active left-sided ulcerative colitis. Alimentary Pharmacology & Therapeutics 2010;31:375-86. [DOI: 10.1111/j.1365-2036.2009.04194.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
47 Kovesdy CP, Kalantar-zadeh K. Inflammation in Chronic Kidney Disease. Chronic Kidney Disease, Dialysis, and Transplantation 2010. [DOI: 10.1016/b978-1-4377-0987-2.00013-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Bridges AW, García AJ. Anti-inflammatory polymeric coatings for implantable biomaterials and devices. J Diabetes Sci Technol 2008;2:984-94. [PMID: 19885288 DOI: 10.1177/193229680800200628] [Cited by in Crossref: 126] [Cited by in F6Publishing: 132] [Article Influence: 9.7] [Reference Citation Analysis]
49 Akyol C, Özis E, Çakmak A, Akarsu ES, Kuzu MA. Nadroparine Blunts Lipopolysaccharide-Induced Hypothermia and Behavioral Depression in Mice. Journal of Investigative Surgery 2009;21:311-7. [DOI: 10.1080/08941930802348253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
50 Kang ES, Acchiardo SR, Kang AH. Implications for the role of endogenous nitric oxide inhibitors in hemodialysis hypotension. Free Radical Research 2009;35:341-65. [DOI: 10.1080/10715760100300871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
51 Mousa SA. Emerging Links Between Thrombosis, Inflammation, and Angiogenesis: Key Role of Heparin and Low-Molecular-Weight Heparins. Fundamental and Clinical Cardiology Series 2009. [DOI: 10.3109/9781420069242.017] [Reference Citation Analysis]
52 Qi J, Li Y, Zhang H, Cheng Y, Sun Y, Cao J, Zhao Y, Wang F. A novel conjugate of low-molecular-weight heparin and Cu,Zn-superoxide dismutase: Study on its mechanism in preventing brain reperfusion injury after ischemia in gerbils. Brain Research 2009;1260:76-83. [DOI: 10.1016/j.brainres.2008.12.079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
53 Rullan M, Cerdà L, Frontera G, Masmiquel L, Llobera J. Authors' response to 'Comments on the use of bemiparin in diabetic foot ulcers'. Diabet Med 2009;26:313-4. [PMID: 19317831 DOI: 10.1111/j.1464-5491.2009.02670.x] [Reference Citation Analysis]
54 Hoppensteadt D, Fareed J, Klein AL, Jasper SE, Apperson-Hansen C, Lieber EA, Katz WE, Malouf JF, Stoddard MF, Pape LA; Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Investigators. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. Am J Cardiol 2008;102:842-6. [PMID: 18805108 DOI: 10.1016/j.amjcard.2008.05.025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
55 Celasco G, Moro L, Bozzella R, Mangano K, Quattrocchi C, Aiello C, Donia M, Fagone P, Di Marco R. Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci 2008;53:3170-5. [PMID: 18465235 DOI: 10.1007/s10620-008-0299-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
56 Kovesdy CP, Kalantar-Zadeh K. Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs 2008;17:451-67. [PMID: 18363512 DOI: 10.1517/13543784.17.4.451] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
57 Barkay O, Niv E, Santo E, Bruck R, Hallak A, Konikoff FM. Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc 2008;22:1971-6. [PMID: 18214607 DOI: 10.1007/s00464-007-9738-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
58 Orr Y, Taylor JM, Cartland S, Bannon PG, Geczy C, Kritharides L. Conformational activation of CD11b without shedding of L-selectin on circulating human neutrophils. J Leukoc Biol 2007;82:1115-25. [PMID: 17675559 DOI: 10.1189/jlb.0906545] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
59 Lever R, Lo WT, Faraidoun M, Amin V, Brown RA, Gallagher J, Page CP. Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol 2007;151:837-43. [PMID: 17533420 DOI: 10.1038/sj.bjp.0707298] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
60 He G, Ouyang Q, Chen D, Li F, Zhou J. The microvascular thrombi of colonic tissue in ulcerative colitis. Dig Dis Sci. 2007;52:2236-2240. [PMID: 17429731 DOI: 10.1007/s10620-006-9158-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
61 Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-994. [PMID: 17012969 DOI: 10.1097/01.mib.0000231495.92013.5e] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 5.3] [Reference Citation Analysis]
62 Manduteanu I, Dragomir E, Voinea M, Capraru M, Simionescu M. Enoxaparin reduces H2O2-induced activation of human endothelial cells by a mechanism involving cell adhesion molecules and nuclear transcription factors. Pharmacology 2007;79:154-62. [PMID: 17259746 DOI: 10.1159/000098952] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
63 Proudfoot A. The biological relevance of chemokine–proteoglycan interactions. Biochemical Society Transactions 2006;34:422-6. [DOI: 10.1042/bst0340422] [Cited by in Crossref: 118] [Cited by in F6Publishing: 124] [Article Influence: 7.4] [Reference Citation Analysis]
64 Brown RA, Allegra L, Matera MG, Page CP, Cazzola M. Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 2006;19:419-24. [PMID: 16807023 DOI: 10.1016/j.pupt.2006.04.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
65 Brookes ZL, Reilly CS, Lawton BK, Brown NJ. INTRAVENOUS ANESTHESIA INHIBITS LEUKOCYTE-ENDOTHELIAL INTERACTIONS AND EXPRESSION OF CD11B AFTER HEMORRHAGE. Shock 2006;25:492-9. [DOI: 10.1097/01.shk.0000209541.76305.8e] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
66 Gallagher H, Ramsay SC, Barnes J, Maggs J, Cassidy N, Ketheesan N. Neutrophil labeling with [99mTc]-technetium stannous colloid is complement receptor 3-mediated and increases the neutrophil priming response to lipopolysaccharide. Nuclear Medicine and Biology 2006;33:433-9. [DOI: 10.1016/j.nucmedbio.2005.12.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
67 Deepa PR, Varalakshmi P. Favourable modulation of the inflammatory changes in hypercholesterolemic atherogenesis by a low-molecular-weight heparin derivative. Int J Cardiol 2006;106:338-47. [PMID: 16337042 DOI: 10.1016/j.ijcard.2005.02.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
68 Deepa P, Varalakshmi P. Biochemical evaluation of the inflammatory changes in cardiac, hepatic and renal tissues of adriamycin-administered rats and the modulatory role of exogenous heparin-derivative treatment. Chemico-Biological Interactions 2005;156:93-100. [DOI: 10.1016/j.cbi.2005.07.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
69 Lombard E, Marin V, Domingo N, Grès S, Lorec A, Saunier V, Arlotto E, Portugal H, Lairon D, Farnarier C, Chanussot F. Anionic Peptide Factor/Phosphatidylcholine Particles Promote the Inhibition of Vascular Cell Adhesion Molecule-1 in Human Umbilical Vein Endothelial Cells. Pathobiology 2005;72:213-9. [DOI: 10.1159/000086791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
70 Pevni D, Frolkis I, Shapira I, Schwartz D, Yuhas Y, Schwartz IF, Chernichovski T, Uretzky G. Heparin Added to Cardioplegic Solution Inhibits Tumor Necrosis Factor-α Production and Attenuates Myocardial Ischemic-Reperfusion Injury. Chest 2005;128:1805-11. [DOI: 10.1378/chest.128.3.1805] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
71 Maciejczyk-Pencuła M, Polak G, Kotarski J. Serum acute phase protein concentrations after hysterectomy with and without low-molecular-weight heparin thrombosis prophylaxis. Acta Obstet Gynecol Scand 2005;84:752-5. [PMID: 16026400 DOI: 10.1111/j.0001-6349.2005.00722.x] [Reference Citation Analysis]
72 Keshavarzian A, Farhadi A, Mutlu EA. New developments in the treatment of inflammatory bowel disease. Expert Opinion on Investigational Drugs 2005;11:365-85. [DOI: 10.1517/13543784.11.3.365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
73 Mousa SA. Heparin and Low Molecular Weight Heparin in Thrombosis and Inflammation. Chemistry and Biology of Heparin and Heparan Sulfate. Elsevier; 2005. pp. 571-81. [DOI: 10.1016/b978-008044859-6/50021-6] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
74 Rabenstein T, Fischer B, Wiessner V, Schmidt H, Radespiel-Tröger M, Hochberger J, Mühldorfer S, Nusko G, Messmann H, Schölmerich J. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc. 2004;59:606-613. [PMID: 15114301 DOI: 10.1016/s0016-5107(04)00159-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 1.9] [Reference Citation Analysis]
75 Elsayed E, Becker RC. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 2003;15:11-8. [PMID: 14574071 DOI: 10.1023/a:1026184100030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
76 Bloom S, Kiilerich S, Lassen MR, Forbes A, Leiper K, Langholz E, Irvine EJ, O’Morain C, Lowson D, Orm S. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:871-878. [PMID: 15080848 DOI: 10.1111/j.1365-2036.2004.01926.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 2.3] [Reference Citation Analysis]
77 Fries W, Mazzon E, Sturiale S, Giofré MR, Lo Presti MA, Cuzzocrea S, Campo GM, Caputi AP, Longo G, Sturniolo GC. A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat. Life Sci 2004;74:2749-56. [PMID: 15043989 DOI: 10.1016/j.lfs.2003.10.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
78 Brown RA, Lever R, Jones NA, Page CP. Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro. Br J Pharmacol 2003;139:845-53. [PMID: 12813008 DOI: 10.1038/sj.bjp.0705291] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
79 Xia B, Han H, Zhang KJ, Li J, Guo GS, Gong LL, Zeng XC, Liu JY. Effects of low molecular weight heparin on platelet surface P-selectin expression and serum interleukin-8 production in rats with trinitrobenzene sulphonic acid-induced colitis. World J Gastroenterol 2004; 10(5): 729-732 [PMID: 14991948 DOI: 10.3748/wjg.v10.i5.729] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
80 He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10(3): 309-318 [PMID: 14760748 DOI: 10.3748/wjg.v10.i3.309] [Cited by in CrossRef: 179] [Cited by in F6Publishing: 186] [Article Influence: 9.9] [Reference Citation Analysis]
81 Videm V. Endpoint-attached heparin blocks neutrophil sticking and spreading. Biomaterials 2004;25:43-51. [DOI: 10.1016/s0142-9612(03)00470-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
82 Floris S, van den Born J, van der Pol SM, Dijkstra CD, De Vries HE. Heparan sulfate proteoglycans modulate monocyte migration across cerebral endothelium. J Neuropathol Exp Neurol 2003;62:780-90. [PMID: 12901703 DOI: 10.1093/jnen/62.7.780] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
83 Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am. 2002;31:147-166. [PMID: 12122729 DOI: 10.1016/s0889-8553(01)00010-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
84 Wolf R, Orion E, Matz H, Tüzün Y, Tüzün B. Miscellaneous treatments, II: niacin and heparin: unapproved uses, dosages, or indications. Clinics in Dermatology 2002;20:547-57. [DOI: 10.1016/s0738-081x(02)00268-7] [Reference Citation Analysis]
85 Sasaki M, Namioka Y, Ito T, Izumiyama N, Fukui S, Watanabe A, Kashima M, Sano M, Shioya T, Miura M. Role of ICAM-1 in the aggregation and adhesion of human alveolar macrophages in response to TNF-alpha and INF-gamma. Mediators Inflamm 2001;10:309-13. [PMID: 11817671 DOI: 10.1080/09629350120102325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
86 Norman D, Miller Y, Sabo E, Misselevich I, Peskin B, Zinman C, Levin D, Reis DN, Boss JH. The effects of enoxaparin on the reparative processes in experimental osteonecrosis of the femoral head of the rat. APMIS 2002;110:221-8. [PMID: 12076275 DOI: 10.1034/j.1600-0463.2002.100304.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
87 Gabrielli M, Pola P, Gasbarrini A. Helicobacter pylori , CagA-Positive Strains, and Ischemic Stroke. Stroke 2002;33:1453-4. [DOI: 10.1161/01.str.0000016298.42331.9d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
88 Rabenstein T, Roggenbuck S, Framke B, Martus P, Fischer B, Nusko G, Muehldorfer S, Hochberger J, Ell C, Hahn EG. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc. 2002;55:476-483. [PMID: 11923757 DOI: 10.1067/mge.2002.122616] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 2.4] [Reference Citation Analysis]
89 O'regan AW, Sadeh J, Berman JS. The effect of unfractionated heparin on circulating lymphocyte counts and subsets in humans. Thrombosis Research 2002;106:31-3. [DOI: 10.1016/s0049-3848(02)00092-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-8. [DOI: 10.1038/nrd724] [Cited by in Crossref: 243] [Cited by in F6Publishing: 257] [Article Influence: 12.2] [Reference Citation Analysis]
91 Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Rundle AC, Gibson CM, Barron HV; Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study Group. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001;104:2778-83. [PMID: 11733394 DOI: 10.1161/hc4801.100236] [Cited by in Crossref: 123] [Cited by in F6Publishing: 133] [Article Influence: 6.2] [Reference Citation Analysis]
92 Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White CR, Bullard DC, Brennan ML, Lusis AJ, Moore KP, Freeman BA. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001;108:1759-1770. [PMID: 11748259 DOI: 10.1172/jci12617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 90] [Article Influence: 0.2] [Reference Citation Analysis]
93 Panés J. Inflammatory bowel disease: pathogenesis and targets for therapeutic interventions. Acta Physiol Scand. 2001;173:159-165. [PMID: 11678739 DOI: 10.1046/j.1365-201X.2001.00905.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
94 Smailbegovic A, Lever R, Page CP. The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells. Br J Pharmacol 2001;134:827-36. [PMID: 11606323 DOI: 10.1038/sj.bjp.0704321] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
95 Holtmann MH, Galle PR, Neurath MF. Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opin Biol Ther 2001;1:455-66. [PMID: 11727518 DOI: 10.1517/14712598.1.3.455] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
96 Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White CR, Bullard DC, Brennan M, Lusis AJ, Moore KP, Freeman BA. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 2001;108:1759-70. [DOI: 10.1172/jci200112617] [Cited by in Crossref: 251] [Cited by in F6Publishing: 250] [Article Influence: 12.0] [Reference Citation Analysis]
97 Michell NP, Lalor P, Langman MJ. Heparin therapy for ulcerative colitis? Effects and mechanisms. Eur J Gastroenterol Hepatol. 2001;13:449-456. [PMID: 11338079 DOI: 10.1097/00042737-200104000-00026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
98 Lever R, Page C. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness. Pulm Pharmacol Ther 2001;14:249-54. [PMID: 11448151 DOI: 10.1006/pupt.2001.0296] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 1.6] [Reference Citation Analysis]
99 Lever R, Smailbegovic A, Page C. Role of glycosaminoglycans in inflammation. Inflammopharmacology 2001;9:165-9. [DOI: 10.1163/156856001300248443] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
100 Panés J, Piqué JM. Reply. Gastroenterology 2001;120:1307-1308. [DOI: 10.1016/s0016-5085(01)87915-4] [Reference Citation Analysis]
101 Panés J, Esteve M, Cabré E, Hinojosa J, Andreu M, Sans M, Fernandez-Bañares F, Feu F, Gassull MA, Piqué JM. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology. 2000;119:903-908. [PMID: 11040177 DOI: 10.1053/gast.2000.18159] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 3.4] [Reference Citation Analysis]